Carboxymethyl Lysine Antibody (CML26)

• Reactivity: Hu
• Applications: WB, ELISA, ICC/IF, IHC
• Clone: CML26
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: 0.1 mg/ml

Carboxymethyl Lysine Antibody (CML26) Summary

• Immunogen: CML-KLH
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • Immunoassay
  • Immunocytochemistry/ Immunofluorescence
  • Immunohistochemistry-Frozen
  • Immunohistochemistry-Paraffin
  • Western Blot
• Application Notes: For immunohistochemistry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user's experimental setting.

Packaging, Storage & Formulations

• Storage: Store at 4C.
• Buffer: 0.2 um filtered solution in PBS, 0.1% BSA
• Preservative: 0.02% Sodium Azide
• Concentration: 0.1 mg/ml
• Purity: Protein G purified

Alternate Names for Carboxymethyl Lysine Antibody (CML26)

• Carboxymethyl Lysine
• CML

Background

The monoclonal antibody CML26 recognizes human CML (carboxymethyl-lysine). CML is known to be formed from the oxidation of both carbohydrates and lipids. This makes CML- a biomarker of general oxidative stress. Carboxymethyl-lysine (CML) is a well-characterized glycoxidation product that accumulates in tissues with age, and its rate of accumulation is accelerated in diabetes. Glycoxidation products are a subset of advanced glycation endproducts (AGEs) that are formed by the nonenzymatic glycation and subsequent irreversible oxidation of proteins. Oxidative stress and protein modification have been implicated in the pathogenesis of the chronic complications of diabetes, including nephropathy and atherosclerosis. The accumulation of CML in long-lived tissue such as skin collagen reflects oxidative stress over an extended period of the life-span, and has been shown to be greater in patients with diabetic complications than those without complications.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.